Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJDA1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS 3	JUN 06	KOREAPAT updated with 41,000 documents
NEWS 4	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS 5	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS 6	JUN 25	CA/CAplus and USPAT databases updated with IPC reclassification data
NEWS 7	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS 8	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations
NEWS 9	JUN 30	STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in
NEWS 10	JUN 30	STN AnaVist enhanced with database content from EPFULL
NEWS 11	JUL 28	CA/CAplus patent coverage enhanced
NEWS 12	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS 13	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS 14	JUL 28	STN Viewer performance improved
NEWS 15	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS 16	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS 17	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS 18	AUG 15	CAplus currency for Korean patents enhanced
NEWS 19	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS 20	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS 21	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS 22	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS 23	SEP 29	IFICLS enhanced with new super search field
NEWS 24	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS 25	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS 26	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS 27	OCT 07	Multiple databases enhanced for more flexible patent number searching

```
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
              AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

 NEWS HOURS     STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN     Welcome Banner and News Items
 NEWS IPC8      For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:26:09 ON 14 OCT 2008

=> file registry
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:26:41 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   12 OCT 2008  HIGHEST RN 1060442-20-7
DICTIONARY FILE UPDATES:  12 OCT 2008  HIGHEST RN 1060442-20-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10783927_specie_chain.str
```



chain nodes :
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
chain bonds :
1-2 1-5 2-3 3-4 3-14 5-6 5-7 6-15 7-8 8-9 9-10 10-11 11-12 12-13
exact/norm bonds :
2-3 3-4 3-14 5-6 6-15 7-8 8-9 9-10
exact bonds :
1-2 1-5 5-7 10-11 11-12 12-13

Match level :
1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 11:27:43 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -      249 TO ITERATE

100.0% PROCESSED      249 ITERATIONS                                  7 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          4034 TO     5926
PROJECTED ANSWERS:                7 TO      298

L2            7 SEA SSS SAM L1

=> d l2 1-7

L2   ANSWER 1 OF 7  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   443883-13-4  REGISTRY
ED   Entered STN:  14 Aug 2002
CN   3,5-Dioxa-9-aza-4-phosphaundecan-1-aminium,
     4-hydroxy-N,N,N-trimethyl-7-(octadecyloxy)-10-oxo-, inner salt, 4-oxide
     (9CI)  (CA INDEX NAME)
MF   C28 H59 N2 O6 P
SR   CA
LC   STN Files:   CA, CAPLUS, CASREACT
```



```
                1 REFERENCES IN FILE CA (1907 TO DATE)
                1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2   ANSWER 2 OF 7  REGISTRY  COPYRIGHT 2008 ACS on STN
RN   210418-12-5  REGISTRY
ED   Entered STN:  26 Aug 1998
CN   3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium,
     4-hydroxy-7-methoxy-N,N,N-trimethyl-10-oxo-, chloride, 4-oxide (9CI)  (CA
     INDEX NAME)
MF   C27 H58 N2 O6 P . Cl
SR   CAS Client Services
CRN  (742681-49-8)
```



L2 ANSWER 3 OF 7 REGISTRY COPYRIGHT 2008 ACS on STN
RN 207298-97-3 REGISTRY
ED Entered STN: 17 Jun 1998
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium,
    4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI)
    (CA INDEX NAME)
MF C26 H55 N2 O6 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 4 OF 7 REGISTRY COPYRIGHT 2008 ACS on STN
RN 207298-94-0 REGISTRY
ED Entered STN: 17 Jun 1998
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
    7-(hexyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI)
    (CA INDEX NAME)
MF C26 H55 N2 O6 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER



2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 5 OF 7 REGISTRY COPYRIGHT 2008 ACS on STN
RN 207298-93-9 REGISTRY
ED Entered STN: 17 Jun 1998
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
    4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI)
    (CA INDEX NAME)
MF C28 H59 N2 O6 P
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL



4 REFERENCES IN FILE CA (1907 TO DATE)
4 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 6 OF 7 REGISTRY COPYRIGHT 2008 ACS on STN
RN 74471-34-4 REGISTRY
ED Entered STN: 16 Nov 1984
CN 9,12-Octadecadienoic acid (9Z,12Z)-,
1-[[[(2-aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-
oxodecyl)amino]ethyl ester (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 9,12-Octadecadienoic acid (Z,Z)-, 1-[[[(2-
aminoethoxy)hydroxyphosphinyl]oxy]methyl]-2-[(1-oxodecyl)amino]ethyl ester
FS STEREOSEARCH
MF C33 H63 N2 O7 P
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 7 OF 7 REGISTRY COPYRIGHT 2008 ACS on STN
RN 74471-25-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN 3,5,8-Trioxa-4-phosphahexacosa-17,20-dien-1-aminium,
4-hydroxy-N,N,N-trimethyl-9-oxo-7-[[(1-oxodecyl)amino]methyl]-, inner
salt, 4-oxide, (Z,Z)- (9CI) (CA INDEX NAME)
FS STEREOSEARCH
MF C36 H69 N2 O7 P
LC STN Files: CA, CAPLUS, TOXCENTER, USPATFULL

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

```
=> s l2 full
FULL SEARCH INITIATED 11:28:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -     4927 TO ITERATE

100.0% PROCESSED     4927 ITERATIONS                                70 ANSWERS
SEARCH TIME: 00.00.01

L3           70 SEA SSS FUL L1

=> file medline caplus wpids uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   193.28     193.49

FILE 'MEDLINE' ENTERED AT 11:28:13 ON 14 OCT 2008

FILE 'CAPLUS' ENTERED AT 11:28:13 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 11:28:13 ON 14 OCT 2008
COPYRIGHT (C) 2008 THOMSON REUTERS

FILE 'USPATFULL' ENTERED AT 11:28:13 ON 14 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l3
SAMPLE SEARCH INITIATED 11:28:17 FILE 'WPIDS'
SAMPLE SCREEN SEARCH COMPLETED -       14 TO ITERATE

100.0% PROCESSED       14 ITERATIONS                                 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE   **COMPLETE**
                        BATCH    **COMPLETE**
```

```
PROJECTED ITERATIONS:           28 TO      252
PROJECTED ANSWERS:               1 TO       40

L4          49 L3

=> s l4 and virus
L5          22 L4 AND VIRUS

=> s l5 and ("corona" or "toga")
L6           0 L5 AND ("CORONA" OR "TOGA")

=> s l5 and (coronavirus or togavirus)
L7           2 L5 AND (CORONAVIRUS OR TOGAVIRUS)

=> d l7 1-2 ibib, abs, hitstr

L7   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2005:904330  CAPLUS
DOCUMENT NUMBER:         143:222464
TITLE:                   Phospholipids for the treatment of infection by
                         togaviruses, herpes viruses and coronaviruses
INVENTOR(S):             Fleming, Ronald A.; Hes, Jan V.; Huang, Yunsheng;
                         Read, Russ H.; Morris-Natschke, Susan L.; Ishaq,
                         Khalid S.; Kucera, Louis S.; Furman, Phillip A.
PATENT ASSIGNEE(S):      Kucera Pharmaceutical Company, USA
SOURCE:                  U.S. Pat. Appl. Publ., 36 pp.
                         CODEN: USXXCO
DOCUMENT TYPE:           Patent
LANGUAGE:                English
FAMILY ACC. NUM. COUNT:  1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    -------------------    --------
     US 20050187192       A1    20050825    US 2004-783927         20040220
PRIORITY APPLN. INFO.:                      US 2004-783927         20040220
OTHER SOURCE(S):         MARPAT 143:222464
AB   Provided are compds., methods and pharmaceutical compns. for treating a
     host, especially a human, infected with a togavirus, herpes
     virus and/or coronavirus, and in particular SARS-CoV,
     cytomegalovirus or varicella-zoster virus.  The method in one
     embodiment comprises administering to that host an effective amount of an
     anti-togavirus, anti-herpes virus and/or anti-
     coronavirus phospholipid or a pharmaceutically acceptable salt or
     prodrug thereof.  The phospholipid compound is, e.g., a
     3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof.  The
     compound may be administered alone or in combination and/or alternation with
     one or more other antiviral agents.  The EC50 of an
     alkylamido-2-alkoxypropylphosphocholine against varicella zoster
     virus was 0.48 μg/mL.
IT   252371-27-0 443882-90-4 443882-91-5
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (phospholipids for treatment of infection by togaviruses, herpes
        viruses and coronaviruses)
RN   252371-27-0  CAPLUS
CN   3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium,
     7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI)
     (CA INDEX NAME)
```



RN 443882-90-4 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-91-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L7 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER:	2005:215516 USPATFULL
TITLE:	Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
INVENTOR(S):	Fleming, Ronald A., Cary, NC, UNITED STATES Hes, Jan V., Hurdle Mills, NC, UNITED STATES Huang, Yunsheng, Apex, NC, UNITED STATES Read, Russ H., Rural Hall, NC, UNITED STATES Morris-Natschke, Susan L., Apex, NC, UNITED STATES Ishaq, Khalid S., Chapel Hill, NC, UNITED STATES Kucera, Louis S., Pfaffown, NC, UNITED STATES Furman, Phillip A., Durham, NC, UNITED STATES
PATENT ASSIGNEE(S):	Kucera Pharmaceutical Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050187192	A1	20050825
APPLICATION INFO.:	US 2004-783927	A1	20040220 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Madeline I. Johnston, Esq., KING & SPALDING LLP, 45th Floor, 191 Peachtree Street, N.E., Atlanta, GA, 30303, US		
NUMBER OF CLAIMS:	65		
EXEMPLARY CLAIM:	1		

NUMBER OF DRAWINGS: 2 Drawing Page(s)
LINE COUNT: 2757
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus , herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 2523/1-27-0 443882-90-4 443882-91-5
(phospholipids for treatment of infection by togaviruses, herpes viruses and coronaviruses)
RN 2523/1-27-0 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-90-4 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-91-5 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



=> d l5 1-22 ibib, abs, hitstr

L5 ANSWER 1 OF 22 MEDLINE on STN
ACCESSION NUMBER: 1991202492 MEDLINE
DOCUMENT NUMBER: PubMed ID: 2016713
TITLE: In vitro evaluation of phosphocholine and quaternary ammonium containing lipids as novel anti-HIV agents.
AUTHOR: Meyer K L; Marasco C J Jr; Morris-Natschke S L; Ishaq K S; Piantadosi C
CORPORATE SOURCE: University of North Carolina, School of Pharmacy, Division of Medicinal Chemistry and Natural Products, Chapel Hill 27599.
CONTRACT NUMBER: CA 12197 (United States NCI)
CA 42216 (United States NCI)
RR 05404 (United States NCRR)
SOURCE: Journal of medicinal chemistry, (1991 Apr) Vol. 34, No. 4, pp. 1377-83.
Journal code: 9716531. ISSN: 0022-2623.
PUB. COUNTRY: United States
DOCUMENT TYPE: (COMPARATIVE STUDY)
Journal; Article; (JOURNAL ARTICLE)
(RESEARCH SUPPORT, NON-U.S. GOV'T)
(RESEARCH SUPPORT, U.S. GOV'T, P.H.S.)
LANGUAGE: English
FILE SEGMENT: Priority Journals; AIDS
ENTRY MONTH: 199105
ENTRY DATE: Entered STN: 7 Jun 1991
Last Updated on STN: 3 Feb 1997
Entered Medline: 21 May 1991

AB A series of synthetic lipids containing a two- or three-carbon backbone substituted with a thio, oxy, or amidoalkyl functionality and either a phosphocholine or quaternary ammonium moiety was evaluated as potential anti-HIV-1 agents. Several analogues were identified as possessing activity with the most promising compound being rac-3-octadecanamido-2-ethoxypropylphosphocholine (8). Compound 8 exhibited an IC50 for the inhibition of plaque formation of 0.16 microM which was 84-fold lower than the IC50 value determined for CEM-SS cell growth inhibition. Initial mechanistic studies have indicated that these compounds, unlike AZT, are not reverse transcriptase (RT) inhibitors, but instead appear to inhibit a late step in HIV replication involving virus assembly and infectious virus production. Since these lipids are acting via a different mechanism, they represent an alternative approach to the chemotherapeutic treatment of AIDS as well as candidates for combination therapy with AZT.

L5 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:904330 CAPLUS
DOCUMENT NUMBER: 143:222464
TITLE: Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
INVENTOR(S): Fleming, Ronald A.; Hes, Jan V.; Huang, Yunsheng; Read, Russ H.; Morris-Natschke, Susan L.; Ishaq, Khalid S.; Kucera, Louis S.; Furman, Phillip A.
PATENT ASSIGNEE(S): Kucera Pharmaceutical Company, USA
SOURCE: U.S. Pat. Appl. Publ., 36 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20050187192	A1	20050825	US 2004-783927	20040220
PRIORITY APPLN. INFO.:			US 2004-783927	20040220

OTHER SOURCE(S): MARPAT 143:222464

AB Provided are compds., methods and pharmaceutical compns. for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other antiviral agents. The EC50 of an alkylamido-2-alkoxypropylphosphocholine against varicella zoster virus was 0.48 μg/mL.

IT 252371-27-0 443882-90-4 443882-91-5
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phospholipids for treatment of infection by togaviruses, herpes viruses and coronaviruses)

RN 252371-27-0 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-90-4 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-91-5 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L5 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:902611 CAPLUS
DOCUMENT NUMBER: 143:241938
TITLE: Methods and compositions for the treatment of respiratory syncytial virus
INVENTOR(S): Kucera, Louis S.; Morris-Natschke, Susan L.; Ishaq, Khalid S.; Fleming, Ronald A.; Hess, Jan V.; Huang, Yunsheng; Read, Russ H.; Furman, Phillip A.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 29 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050187191	A1	20050825	US 2004-781894	20040220
WO 2005099719	A2	20051027	WO 2005-US3972	20050209
WO 2005099719	A3	20070322		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-781894 A 20040220
OTHER SOURCE(S): MARPAT 143:241938

AB The invention includes compds. useful for inhibiting RSV replication and treating a host infected with RSV. The invention also includes methods of treating a host infected with RSV by administering to the host an anti-RSV effective amount of a compound of the invention.

IT 443882-90-4, KPC 11 443882-91-5, KPC 15
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (compns. for treatment of respiratory syncytial virus)

RN 443882-90-4 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-91-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



IT 207298-91-7 207298-93-9 252371-27-0
443882-96-0
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. for treatment of respiratory syncytial virus)
RN 207298-91-7 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-(dodecyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-93-9 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 252371-27-0 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-96-0 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-butoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:435743 CAPLUS
DOCUMENT NUMBER: 129:90448
ORIGINAL REFERENCE NO.: 129:18491a,18494a
TITLE: Method of treating hepatitis virus infections
INVENTOR(S): Kucera, Louis S.; Morris-Natschke, Susan L.
PATENT ASSIGNEE(S): Wake Forest University, USA; University of North Carolina
SOURCE: U.S., 17 pp., Cont.-in-part of U. S. Ser. No. 74,943, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5770584	A	19980623	US 1995-465947	19950606
US 6030960	A	20000229	US 1998-102308	19980622
PRIORITY APPLN. INFO.:			US 1993-74943	B2 19930610
			US 1995-465947	A3 19950606

OTHER SOURCE(S): MARPAT 129:90448
AB A method of treating hepatitis virus infection is disclosed. The method involves administering to a human subject in need of such treatment an effective hepatitis virus-combating amount of an alkyl lipid or alkyl lipid derivative
IT 112989-01-2P 112989-02-3P 209532-02-5P 209532-03-6P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(alkyl lipids for treating hepatitis virus infections)
RN 112989-01-2 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-02-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 209532-02-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 209532-03-6 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:205430 CAPLUS
DOCUMENT NUMBER: 128:316940
ORIGINAL REFERENCE NO.: 128:62637a,62640a
TITLE: In vitro evaluation and characterization of newly designed alkylamidophospholipid analogs as anti-human immunodeficiency virus type 1 agents
AUTHOR(S): Kucera, L. S.; Iyer, N.; Morris-Natschke, S. L.; Chen, S. Y.; Gumus, F.; Ishaq, K.; Herrmann, D. B. J.
CORPORATE SOURCE: Wake Forest University School Medicine, Winston-Salem, NC, USA
SOURCE: Antiviral Chemistry & Chemotherapy (1998), 9(2), 157-165
CODEN: ACCHEH; ISSN: 0956-3202
PUBLISHER: International Medical Press
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Our labs. first reported two novel classes of complex synthetic lipids, including alkylamidophosphocholines (PC lipid; CP-51) and alkylamidophosphate ester-linked lipid-AZT conjugates (lipid-AZT

conjugates; CP-92), with selective and potent activity against human immunodeficiency virus type 1 (HIV-1). To extend these observations, we synthesized addnl. PC lipids and lipid-AZT conjugates (INK and INK-AZT conjugate) to evaluate their structure-activity relationships by testing for selectivity against infectious wild-type (wt) and drug-resistant HIV-1 replication, virus fusogenic activity and toxicity replication, virus fusogenic activity and toxicity for mouse bone marrow cells. PC lipid compds. with medium chain lengths at positions 1 and 2 gave an improved selective index (SI). INK-3, with 12 and 8 carbons and INK-15, with 10 and 12 carbons were among the most selective when evaluated in CEM-SS cells. INK-14, a lipid-AZT conjugate where AZT replaced the choline in PC lipid INK-3, gave the highest SI of >1250 against both infectious wt HIV-1 replication in CEM-SS cells and a clin. isolate in peripheral blood leukocytes. Notably, the PC lipid compds. INK-3 and INK-15, but not the lipid-AZT conjugate INK-14, were potent inhibitors of matched pairs of AZT-sensitive and AZT-resistant HIV-1 clin. isolates. INK-3 also inhibited replication of HIV-2 and TIBO-resistant HIV-1, and inhibited HIV-1-mediated fusogenic activity by 78, 41 and 9% in a dose-dependent manner. The TC50 for mouse bone marrow cells was >100 μg/mL for CP-51 and 0.142-0.259 μg/mL for AZT. These data suggest that optimum PC lipid compds. are significantly less toxic than AZT and have high potential as novel therapeutic agents for AIDS.

IT 207298-91-7P 207298-92-8P 207298-93-9P
207298-94-0P 207298-95-1P 207298-97-3P
207298-99-5P
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(anti-HIV-1 activity and preparation of alkylamidophospholipid analogs)

RN 207298-91-7 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-(dodecyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-92-8 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-93-9 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,

4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI)
(CA INDEX NAME)



RN 207298-94-0 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
7-(hexyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI)
(CA INDEX NAME)



RN 207298-95-1 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium,
4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI)
(CA INDEX NAME)



RN 207298-97-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium,
4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI)
(CA INDEX NAME)



RN 207298-99-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium,
7-(dodecyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide
(9CI) (CA INDEX NAME)



IT 112989-02-3, CP 51
RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(anti-HIV-1 activity and preparation of alkylamidophospholipid analogs)
RN 112989-02-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:388263 CAPLUS
DOCUMENT NUMBER: 125:49273
ORIGINAL REFERENCE NO.: 125:9233a,9236a
TITLE: Lipid analogs for treating viral infections
INVENTOR(S): Kucera, Louis S.; Morris-Natschke, Susan L.; Ishaq, Khalid S.
PATENT ASSIGNEE(S): Wake Forest University, USA; Univ. of North Carolina at Chapel Hill
SOURCE: PCT Int. Appl., 53 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9606620	A2	19960307	WO 1995-US10111	19950807
WO 9606620	A3	19960613		
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2197319	A1	19960307	CA 1995-2197319	19950807
AU 9532166	A	19960322	AU 1995-32166	19950807

EP 781138	A2	19970702	EP 1995-928365	19950807
EP 781138	B1	20080521		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 10506619	T	19980630	JP 1995-508773	19950807
EP 1852121	A2	20071107	EP 2007-16369	19950807
EP 1852121	A3	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 395922	T	20080615	AT 1995-928365	19950807
US 5962437	A	19991005	US 1997-793470	19970502
US 7129227	B1	20061031	US 1999-412539	19991004
US 20040259845	A1	20041223	US 2004-889127	20040713
US 7135584	B2	20061114		
US 20050080050	A1	20050414	US 2004-943923	20040920
US 7141557	B2	20061128		
JP 2007056033	A	20070308	JP 2006-278049	20061011
US 20070099870	A1	20070503	US 2006-588313	20061027
US 7294621	B2	20071113		
US 20070105811	A1	20070510	US 2006-588308	20061027
US 7294619	B2	20071113		
US 20070105812	A1	20070510	US 2006-588311	20061027
US 7294620	B2	20071113		

PRIORITY APPLN. INFO.:	US 1994-297416	A	19940829
	US 1994-314901	A	19940929
	EP 1995-928365	A3	19950807
	JP 1996-508773	A3	19950807
	WO 1995-US10111	W	19950807
	US 1997-793470	A3	19970502
	US 1999-412539	B1	19991004
	US 2004-889127	A3	20040713
	US 2004-943923	A3	20040920

OTHER SOURCE(S): MARPAT 125:49273

AB A method of treating viral infections, in particular with HIV-1, hepatitis B virus, and herpes viruses, is disclosed. The method comprising administering to a subject in need of such treatment an infection-combating amount of a phospholipid or phospholipid derivative For example, 1-dodecanamido-2-decylpropyl-3-phosphocholine showed IC50 value of 0.14 μM against HIV-1 syncytial plaque formation.

IT 178172-98-0 178172-99-1 178173-00-7
178173-01-8
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(phospholipids for treating viral infections and tumors)

RN 178172-98-0 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(decyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178172-99-1 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-[3-(octyloxy)propoxy]-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-00-7 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(dodecyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-01-8 CAPLUS
CN Ethanaminium, 2-[[[2-[2-(dodecyloxy)propoxy]-3-[(1-oxododecyl)amino]propoxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (CA INDEX NAME)



L5 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:701769 CAPLUS
DOCUMENT NUMBER: 123:112632
ORIGINAL REFERENCE NO.: 123:20141a,20144a
TITLE: Phospholipids for combating hepatitis B virus infection
INVENTOR(S): Kucera, Louis S.; Morris-Natschke, Susan L.
PATENT ASSIGNEE(S): Wake Forest University, USA; University of North Carolina
SOURCE: PCT Int. Appl., 38 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9428908	A2	19941222	WO 1994-US5855	19940525

WO 9428908		A3	19950323		
W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KG, KP, KR, KZ, LK, LU, LV, MD, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, TJ, TT, UA, US, UZ, VN					
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
CA 2164717		A1	19941222	CA 1994-2164717	19940525
AU 9470448		A	19950103	AU 1994-70448	19940525
EP 702556		A1	19960327	EP 1994-919231	19940525
EP 702556		B1	20021023		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
AT 226437		T	20021115	AT 1994-919231	19940525
PRIORITY APPLN. INFO.:				US 1993-74943 A	19930610
				WO 1994-US5855 W	19940525

OTHER SOURCE(S): MARPAT 123:112632

GI



I

AB A method of treating infection with hepatitis B virus is disclosed. The method comprises administration of alkyl ether phospholipids and derivs. of formula DCH2XCH2YR1 [Y = S, O, NH, NMe, NHCO, NMeCO; R1 = (un)branched (un)saturated C10-20 alk(en/yn)yl; X = bond, CH2 (un)substituted by OH, alkyl, alkoxy, or alkylthio; D = (PO4)-E, N+R5R6FW Z-; E = (mono/di/trialkyl)ammonioalkyl or a nucleic acid base conjugate; F = alkylene; R5, R6 = H, alkyl; W = OH, SH; Z- = anion]. Several compds. were prepared For example, etherification of isopropylideneglycerol with 1-bromododecane using KOH in PhMe and acid hydrolysis with HCl in MeOH-Et2O mixture gave 71% 3-dodecyloxy-1,2-propanediol. This underwent 1-O-tritylation with Ph3CCl in pyridine, 2-O-alkylation by 1-bromodecane and NaH in THF (51%), and detritylation by p-MeC6H4SO3H in CHCl3-MeOH (63%) to give 3-dodecyloxy-2-decyloxy-1-propanol. The latter underwent esterification with (PhO)2P(O)Cl (60%), hydrogenolysis of the Ph ester to the phosphatidic acid, and reesterification with AZT using DCC (22%) to give title compound (Na salt) I. Another compound, (±)-3-octadecanamido-2-ethoxypropyl-1-phosphocholine, inhibited HBV virion DNA and intracellular RI HBV DNA in expts. to a comparable or greater extent than the standard agent ddC.

IT 112989-01-2P 112989-02-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of phospholipids for combating hepatitis B virus)

RN 112989-01-2 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium,

7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-02-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



L5 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1995:694404 CAPLUS
DOCUMENT NUMBER:	123:160151
ORIGINAL REFERENCE NO.:	123:28207a,28210a
TITLE:	Membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/ gp120 binding to monoclonal antibody
AUTHOR(S):	Krugner-Higby, Lisa; Goff, David; Edwards, Terri; Iyer, Nathan; Neufeld, Jay; Kute, Timothy; Morris-Natschke, Susan; Ishaq, Khalid; Piantadosi, Claude; Kucera, Louis S.
CORPORATE SOURCE:	Wake Forest University, Winsto-Salem, NC, 27157-1064, USA
SOURCE:	AIDS Research and Human Retroviruses (1995), 11(6), 705-12 CODEN: ARHRE7; ISSN: 0889-2229
PUBLISHER:	Liebert
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB Membrane-interactive phospholipids (PLs), previously evaluated for activity against HIV-1 in vitro, are known to affect late steps in viral replication. Studies were done to determine the effects of PL analogs on post-translational processing of HIV-1 proteins, binding of viral surface gp160/gp120 to CD4 receptor, and HIV-1-induced cell fusion. Results of this investigation indicated that PL alone (1-octadecanamido-2-ethoxypropyl-rac-3-phosphocholine, CP-51) and PL-AZT conjugate (1-octadecanamido-2-ethoxypropyl-rac-3-phospho-3'-azido-3'-deoxythymidine, CP-92) have no effect on HIV-1-induced syntheses or processing of gp160/gp120, pr51, p24, or p17 (including myristoylation) in infected cells. Progeny HIV-1 particles made in CP-92-treated H9IIIB cells contained gp120, pr51, and p24; however, these virus particles had reduced capacity to bind to CD4+ cells. Both CP-51 and CP-92 inhibited syncytium (cell fusion) formation between treated HIV-1-infected cells and uninfected CD4+ cells, and, they reduced HIV-1 gp160/gp120 binding to CD4+ cells and monoclonal antibody. These results suggest that anti-HIV-1 activity of PL compds. involves alteration of cell

surface membranes and viral envelopes. Phospholipid compds. are a novel class of membrane interactive compds. with potential use in blocking the spread of HIV-1 infection and pathogenesis in AIDS.

IT 112989-02-3, CP 51
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(membrane-interactive phospholipids inhibit HIV type 1-induced cell fusion and surface gp160/ gp120 binding to monoclonal antibody)

RN 112989-02-3 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



L5 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1991:185901 CAPLUS
DOCUMENT NUMBER:	114:185901
ORIGINAL REFERENCE NO.:	114:31415a,31418a
TITLE:	Synthesis and evaluation of novel ether lipid nucleoside conjugates for anti-HIV-1 activity
AUTHOR(S):	Piantadosi, Claude; Marasco, Canio J., Jr.; Morris-Natschke, Susan L.; Meyer, Karen L.; Gumus, Fatma; Surles, Jefferson R.; Ishaq, Khalid S.; Kucera, Louis S.; Iyer, Nathan; et al.
CORPORATE SOURCE:	Sch. Pharm., Univ. North Carolina, Chapel Hill, NC, 27599, USA
SOURCE:	Journal of Medicinal Chemistry (1991), 34(4), 1408-14 CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 114:185901

GI



I

AB Combinations of an amidoalkylphosphocholine, C17H35CONHCH2CH(OEt)CH2OP(O)(O-)OCH2CH2N+Me3, and AZT were found to cause an apparent synergistic action in suppressing infectious HIV-1 replication. In addition, alkylamido, alkyloxy, and alkylthio ether lipids were chemical linked to anti-HIV-1 nucleosides (AZT and DDI) through phosphate and phosphonate linkages. These conjugates show promising in vitro anti-HIV-1 activity. Also, the conjugates have a 5-10-fold reduction in cell cytotoxicity compared to AZT alone. The most active compound, an alkylamido ether lipid-AZT conjugate, I was found to have a differential selectivity of 1793 in a syncytial plaque assay. In comparison, AZT alone has a value of 1281.

IT 112989-02-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(anti-HIV-1 activity of)

RN 112989-02-3 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



L5 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1991:185881 CAPLUS
DOCUMENT NUMBER:	114:185881
ORIGINAL REFERENCE NO.:	114:31411a,31414a
TITLE:	In vitro evaluation of phosphocholine and quaternary ammonium containing lipids as novel anti-HIV agents
AUTHOR(S):	Meyer, Karen L.; Marasco, Canino J., Jr.; Morris-Natschke, Susan L.; Ishaq, Khalid S.; Piantadosi, Claude; Kucera, Louis S.
CORPORATE SOURCE:	Sch. Pharm., Univ. North Carolina, Chapel Hill, NC, 27599, USA
SOURCE:	Journal of Medicinal Chemistry (1991), 34(4), 1377-83 CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 114:185881

GI



I

AB A series of synthetic lipids containing a two- or three-carbon backbone substituted with a thio, oxy, or amidoalkyl functionality and either a phosphocholine or quaternary ammonium moiety were evaluated as potential anti-HIV-1 agents. Several analogs were identified as possessing activity with the most promising compound being

rac-3-octadecanamido-2-ethoxypropylphosphocholine (I). I exhibited an IC50 for the inhibition of plaque formation of 0.16 μM which was 84-fold lower than the IC50 value determined for CEM-SS cell growth inhibition. Initial mechanistic studies have indicated that these compds., unlike AZT, are not reverse transcriptase (RT) inhibitors, but instead appear to inhibit a late step in HIV replication involving virus assembly and infectious virus production Since these lipids are acting via a different, mechanism they represent an alternative approach to the chemotherapeutic treatment of AIDS as well as candidates for combination therapy with AZT.

IT 88876-07-7 112989-00-1 112989-01-2
112989-02-3
RL: RCT (Reactant); RACT (Reactant or reagent)
(anti-HIV-1 activity of)

RN 88876-07-7 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-00-1 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 4-hydroxy-7-methoxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 112989-01-2 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-02-3 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



IT 149576-20-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and anti-HIV-1 activity of)
RN 149576-20-5 CAPLUS
CN 3,5-Dioxa-9-aza-4-phosphanonacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L5 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:470710 CAPLUS
DOCUMENT NUMBER: 113:70710
ORIGINAL REFERENCE NO.: 113:11741a,11744a
TITLE: Novel membrane-interactive ether lipid analogs that inhibit infectious HIV-1 production and induce defective virus formation
AUTHOR(S): Kucera, Louis S.; Iyer, Nathan; Leake, Eva; Raben, Adam; Modest, Edward J.; Daniel, Larry W.; Piantadosi, Claude
CORPORATE SOURCE: Bowman Gray Sch. Med., Wake Forest Univ., Winston-Salem, NC, 27103, USA
SOURCE: AIDS Research and Human Retroviruses (1990), 6(4), 491-501
CODEN: ARHRE7; ISSN: 0889-2229
DOCUMENT TYPE: Journal
LANGUAGE: English

AB A new class of membrane-active ether lipid (EL) analogs of platelet-activating factor were studied for in vitro anti-HIV-1 activity. Human T-cell (CEM-ss) monolayers or suspension cultures were used to determine effects of structural modifications of Type A phosphorus-containing and Type B nonphosphorus EL analogs on (a) the inhibitory concn.50 (IC50) for HIV-1 syncytial plaque formation and cell growth, and, (b) virus budding at the cell plasma membrane. Results indicate that representative Type A and Type B EL inhibit HIV-1 but not herpes simplex virus type 2 plaque formation when added before or up to 2 days after viral infection. Anti-HIV-1 activity does not involve direct inactivation of virus infectivity. Type A EL (IC50 range = 0.2-1.4 μM) with alkoxy, alkylthio, or alkyamido substitution at glycerol position 1 and ethoxy or methoxy substitution at position 2, and Type B compds. (IC50 range = 0.33-0.63 μM) with an inverse choline or nitrogen heterocyclic substitution at position 3 have selective activity against HIV-1-infected T-cells. EL treatment of HIV-1-infected cells is associated with subsequent release of reverse transcriptase activity, but infectious virus production is inhibited with time after infection. Electron microscopic examination of HIV-1-infected and EL-treated cells revealed absence of

detectable budding virus at the plasma membrane but presence of intracytoplasmic vacuolar virus particles. EL analogs are a novel class of agents that induce defective intracytoplasmic vacuolar HIV-1 formation in T-cells. Being membrane interactive, EL are ideally suited for combination chemotherapy with DNA-interactive anti-HIV nucleoside analogs.

IT 112989-02-3
RL: BIOL (Biological study)
(human immunodeficiency virus infection response to)

RN 112989-02-3 CAPLUS

CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



L5 ANSWER 12 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2007:121606 USPATFULL
TITLE:	Lipid analogs for inhibiting HIV-1 activity
INVENTOR(S):	Kucera, Louis S., Pfafftown, NC, UNITED STATES Morris-Natschke, Susan L., Apex, NC, UNITED STATES Ishaq, Khalid S., Chapel Hill, NC, UNITED STATES
PATENT ASSIGNEE(S):	Wake Forest University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070105812	A1	20070510
	US 7294620	B2	20071113
APPLICATION INFO.:	US 2006-588311	A1	20061027 (11)

RELATED APPLN. INFO.:	Division of Ser. No. US 1999-412539, filed on 4 Oct 1999, GRANTED, Pat. No. US 7129227 Division of Ser. No. US 1997-793470, filed on 2 May 1997, GRANTED, Pat. No. US 5962437 Continuation of Ser. No. US 1994-314901, filed on 29 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-297416, filed on 29 Aug 1994, ABANDONED
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
NUMBER OF CLAIMS:	18
EXEMPLARY CLAIM:	1-106
LINE COUNT:	898

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the activity of the viral infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 178172-98-0 178172-99-1 178173-00-7
178173-01-8
(phospholipids for treating viral infections and tumors)

RN 178172-98-0 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
7-[3-(decyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt,
4-oxide (9CI) (CA INDEX NAME)



RN 178172-99-1 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
4-hydroxy-N,N,N-trimethyl-7-[3-(octyloxy)propoxy]-10-oxo-, inner salt,
4-oxide (9CI) (CA INDEX NAME)



RN 178173-00-7 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
7-[3-(dodecyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt,
4-oxide (9CI) (CA INDEX NAME)



RN 178173-01-8 USPATFULL
CN Ethanaminium, 2-[[[2-[2-(dodecyloxy)propoxy]-3-[(1-
oxododecyl)amino]propoxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner
salt (CA INDEX NAME)



L5 ANSWER 13 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2007:121605 USPATFULL
TITLE:	Lipid analogs for inhibiting the activity of hepatitis B antigen
INVENTOR(S):	Kucera, Louis S., Pfafftown, NC, UNITED STATES Morris-Natschke, Susan L., Apex, NC, UNITED STATES Ishaq, Khalid S., Chapel Hill, NC, UNITED STATES
PATENT ASSIGNEE(S):	Wake Forest University (U.S. corporation) University of North Carolina at Chapel Hill (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070105811	A1	20070510
	US 7294619	B2	20071113
APPLICATION INFO.:	US 2006-588308	A1	20061027 (11)

RELATED APPLN. INFO.:	Division of Ser. No. US 2004-889127, filed on 13 Jul 2004, GRANTED, Pat. No. US 7135584 Division of Ser. No. US 1999-412539, filed on 4 Oct 1999, GRANTED, Pat. No. US 7129227 Division of Ser. No. US 1997-793470, filed on 2 May 1997, GRANTED, Pat. No. US 5962437 Continuation of Ser. No. US 1994-314901, filed on 29 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-297416, filed on 29 Aug 1994, ABANDONED
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
NUMBER OF CLAIMS:	20
EXEMPLARY CLAIM:	1-106
LINE COUNT:	899

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the activity of the viral infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 178172-98-0 178172-99-1 178173-00-7
178173-01-8
(phospholipids for treating viral infections and tumors)

RN 178172-98-0 USPATFULL

CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(decyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178172-99-1 USPATFULL

CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-[3-(octyloxy)propoxy]-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-00-7 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(dodecyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-01-8 USPATFULL
CN Ethanaminium, 2-[[[2-[2-(dodecyloxy)propoxy]-3-[(1-oxododecyl)amino]propoxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (CA INDEX NAME)



L5 ANSWER 14 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2007:114796 USPATFULL
TITLE: Lipid analogs for combating tumors
INVENTOR(S): Kucera, Louis S., Pfafftown, NC, UNITED STATES
Morris-Natschke, Susan L., Apex, NC, UNITED STATES
Ishaq, Khalid S., Chapel Hill, NC, UNITED STATES
PATENT ASSIGNEE(S): Wake Forest University (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20070099870	A1	20070503
	US 7294621	B2	20071113
APPLICATION INFO.:	US 2006-588313	A1	20061027 (11)

RELATED APPLN. INFO.: Division of Ser. No. US 2004-943923, filed on 20 Sep 2004, GRANTED, Pat. No. US 7141557 Continuation of Ser. No. US 1999-412539, filed on 4 Oct 1999, GRANTED, Pat. No. US 7129227 Division of Ser. No. US 1997-793470, filed on 2 May 1997, GRANTED, Pat. No. US 5962437 Continuation of Ser. No. US 1994-314901, filed on 29 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US

1994-297416, filed on 29 Aug 1994, ABANDONED
DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1-106
LINE COUNT: 900
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB The invention relates to methods of treating viral infections, and in particular hepatitis B virus. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative to inhibit the activity of the viral infection.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 178172-98-0 178172-99-1 178173-00-7
178173-01-8
(phospholipids for treating viral infections and tumors)
RN 178172-98-0 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(decyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178172-99-1 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-[3-(octyloxy)propoxy]-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-00-7 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(dodecyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-01-8 USPATFULL
CN Ethanaminium, 2-[[[2-[2-(dodecyloxy)propoxy]-3-[(1-oxododecyl)amino]propoxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (CA INDEX NAME)



L5 ANSWER 15 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2006:284487 USPATFULL
TITLE:	Lipid analogs for treating viral infections
INVENTOR(S):	Kucera, Louis S., Pfafftown, NC, UNITED STATES Morris-Natschke, Susan L., Apex, NC, UNITED STATES Ishaq, Khalid S., Chapel Hill, NC, UNITED STATES
PATENT ASSIGNEE(S):	Wake Forest University, Winston Salem, NC, UNITED STATES (U.S. corporation) University of North Carolina at Chapel Hill, Chapel Hill, NC, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 7129227	B1	20061031
APPLICATION INFO.:	US 1999-412539		19991004 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-793470, Pat. No. US 5962437 A 371 of International Ser. No. WO 1995-US10111, filed on 7 Aug 1995 Continuation of Ser. No. US 1994-314901, filed on 29 Sep 1994, ABANDONED Continuation-in-part of Ser. No. US 1994-297416, filed on 29 Aug 1994, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Coleman, Brenda		
LEGAL REPRESENTATIVE:	Morgan Lewis & Bockius LLP		
NUMBER OF CLAIMS:	24		
EXEMPLARY CLAIM:	1		
LINE COUNT:	1259		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpesviruses, is disclosed. The method comprises administering to a subject in need of such treatment an infection-combating amount of a phospholipid or phospholipid derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 178172-98-0 178172-99-1 178173-00-7
178173-01-8
(phospholipids for treating viral infections and tumors)

RN 178172-98-0 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
7-[3-(decyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt,
4-oxide (9CI) (CA INDEX NAME)



RN 178172-99-1 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
4-hydroxy-N,N,N-trimethyl-7-[3-(octyloxy)propoxy]-10-oxo-, inner salt,
4-oxide (9CI) (CA INDEX NAME)



RN 178173-00-7 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
7-[3-(dodecyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt,
4-oxide (9CI) (CA INDEX NAME)



RN 178173-01-8 USPATFULL
CN Ethanaminium, 2-[[[2-[2-(dodecyloxy)propoxy]-3-[(1-
oxododecyl)amino]propoxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner
salt (CA INDEX NAME)



L5 ANSWER 16 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2005:215516 USPATFULL
TITLE:	Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
INVENTOR(S):	Fleming, Ronald A., Cary, NC, UNITED STATES Hes, Jan V., Hurdle Mills, NC, UNITED STATES Huang, Yunsheng, Apex, NC, UNITED STATES Read, Russ H., Rural Hall, NC, UNITED STATES Morris-Natschke, Susan L., Apex, NC, UNITED STATES Ishaq, Khalid S., Chapel Hill, NC, UNITED STATES Kucera, Louis S., Pfaffown, NC, UNITED STATES Furman, Phillip A., Durham, NC, UNITED STATES
PATENT ASSIGNEE(S):	Kucera Pharmaceutical Company (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050187192	A1	20050825
APPLICATION INFO.:	US 2004-783927	A1	20040220 (10)

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	Madeline I. Johnston, Esq., KING & SPALDING LLP, 45th Floor, 191 Peachtree Street, N.E., Atlanta, GA, 30303, US
NUMBER OF CLAIMS:	65
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	2 Drawing Page(s)
LINE COUNT:	2757

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are compounds, methods and pharmaceutical compositions for treating a host, especially a human, infected with a togavirus, herpes virus and/or coronavirus, and in particular SARS-CoV, cytomegalovirus or varicella-zoster virus. The method in one embodiment comprises administering to that host an effective amount of an anti-togavirus, anti-herpes virus and/or anti-coronavirus phospholipid or a pharmaceutically acceptable salt or prodrug thereof. The phospholipid compound is, e.g., a 3-alkylamido-2-alkoxypropylphosphocholine compound or salt thereof. The compound may be administered alone or in combination and/or alternation with one or more other anti-viral agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 252371-27-0 443882-90-4 443882-91-5
(phospholipids for treatment of infection by togaviruses, herpes viruses and coronaviruses)

RN 252371-27-0 USPATFULL

CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-90-4 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-91-5 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2005:215515 USPATFULL
TITLE:	Methods and compositions for the treatment of respiratory syncytial virus
INVENTOR(S):	Kucera, Louis S., Pfafftown, NC, UNITED STATES Morris-Natschke, Susan L., Apex, NC, UNITED STATES Ishaq, Khalid S., Chapel Hill, NC, UNITED STATES Fleming, Ronald A., Cary, NC, UNITED STATES Hess, Jan V., Hurdle Mills, NC, UNITED STATES Huang, Yunsheng, Apex, NC, UNITED STATES Read, Russ H., Rural Hall, NC, UNITED STATES Furman, Phillip A., Durham, NC, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050187191	A1	20050825
APPLICATION INFO.:	US 2004-781894	A1	20040220 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	2105		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention includes compounds useful for inhibiting RSV replication and treating a host infected with RSV. The invention also includes methods of treating a host infected with RSV by administering to the host an anti-RSV effective amount of a compound of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 443882-90-4, KPC 11 443882-91-5, KPC 15
(compns. for treatment of respiratory syncytial virus)
RN 443882-90-4 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 443882-91-5 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



IT 207298-91-7 207298-93-9 252371-27-0
443882-96-0
(compns. for treatment of respiratory syncytial virus)
RN 207298-91-7 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-(dodecyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 207298-93-9 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-(octyloxy)-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 252371-27-0 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphanonadecan-1-aminium,
7-(decyloxy)-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide
(9CI) (CA INDEX NAME)



RN 443882-96-0 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium,
7-butoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI)
(CA INDEX NAME)



L5 ANSWER 18 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2005:93372 USPATFULL
TITLE:	Lipid analogs for treating viral infections
INVENTOR(S):	Kucera, Louis S., Pfafftown, NC, UNITED STATES Morris-Natschke, Susan L., Apex, NC, UNITED STATES Ishaq, Khalid S., Chapel Hill, NC, UNITED STATES
PATENT ASSIGNEE(S):	Wake Forest University, Winston-Salem, NC, UNITED STATES (U.S. corporation) University of North Carolina at Chapel Hill, Chapel Hill, NC, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050080050	A1	20050414
	US 7141557	B2	20061128
APPLICATION INFO.:	US 2004-943923	A1	20040920 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1999-412539, filed on 4 Oct 1999, PENDING Division of Ser. No. US 1997-793470, filed on 2 May 1997, GRANTED, Pat. No. US 5962437 A 371 of International Ser. No. WO 1995-US10111, filed on 7 Aug 1995

DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION

LEGAL REPRESENTATIVE: MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004, US
NUMBER OF CLAIMS: 34
EXEMPLARY CLAIM: 1-106
LINE COUNT: 960
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpes virus, is disclosed. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 178172-98-0 178172-99-1 178173-00-7 178173-01-8
(phospholipids for treating viral infections and tumors)
RN 178172-98-0 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(decyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178172-99-1 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-[3-(octyloxy)propoxy]-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-00-7 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(dodecyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-01-8 USPATFULL

CN Ethanaminium, 2-[[[2-[2-(dodecyloxy)propoxy]-3-[(1-oxododecyl)amino]propoxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (CA INDEX NAME)



L5 ANSWER 19 OF 22 USPATFULL on STN

ACCESSION NUMBER:	2004:328020 USPATFULL
TITLE:	Lipid analogs for treating viral infections
INVENTOR(S):	Kucera, Louis S., Pfafftown, NC, UNITED STATES Morris-Natschke, Susan L., Apex, NC, UNITED STATES Ishaq, Khalid S., Chapel Hill, NC, UNITED STATES
PATENT ASSIGNEE(S):	Wake Forest University, Winston-Salem, NC (U.S. corporation) University of North Carolina at Chapel Hill, Chapel Hill, NC (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040259845	A1	20041223
	US 7135584	B2	20061114
APPLICATION INFO.:	US 2004-889127	A1	20040713 (10)

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-412539, filed on 4 Oct 1999, ABANDONED Division of Ser. No. US 1997-793470, filed on 2 May 1997, GRANTED, Pat. No. US 5962437 A 371 of International Ser. No. WO 1995-US10111, filed on 7 Aug 1995, PENDING
DOCUMENT TYPE:	Utility
FILE SEGMENT:	APPLICATION
LEGAL REPRESENTATIVE:	MORGAN LEWIS & BOCKIUS LLP, 1111 PENNSYLVANIA AVENUE NW, WASHINGTON, DC, 20004
NUMBER OF CLAIMS:	19
EXEMPLARY CLAIM:	CLM-1-106
LINE COUNT:	903

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating viral infections, and in particular HIV-1, hepatitis B virus, and herpes virus, is disclosed. The method comprises administering to a subject in need of such treatment an infection-controlling amount of a phospholipid or phospholipid derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 178172-98-0 178172-99-1 178173-00-7
178173-01-8
(phospholipids for treating viral infections and tumors)

RN 178172-98-0 USPATFULL

CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(decyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178172-99-1 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-[3-(octyloxy)propoxy]-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-00-7 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(dodecyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-01-8 USPATFULL
CN Ethanaminium, 2-[[[2-[2-(dodecyloxy)propoxy]-3-[(1-oxododecyl)amino]propoxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (CA INDEX NAME)



L5 ANSWER 20 OF 22 USPATFULL on STN
ACCESSION NUMBER: 2000:24634 USPATFULL
TITLE: Method of treating hepatitis virus infections
INVENTOR(S): Morris-Natschke, Susan L., Apex, NC, United States
Kucera, Louis S., Pfafftown, NC, United States

PATENT ASSIGNEE(S): Wake Forest University, Winston-Salem, NC, United States (U.S. corporation)
University of North Carolina at Chapel Hill, Chapel Hill, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6030960		20000229
APPLICATION INFO.:	US 1998-102308		19980622 (9)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-465947, filed on 6 Jun 1995, now patented, Pat. No. US 5770584 which is a continuation-in-part of Ser. No. US 1993-74943, filed on 10 Jun 1993, now abandoned
DOCUMENT TYPE: Utility
FILE SEGMENT: Granted
PRIMARY EXAMINER: Wilson, James O.
LEGAL REPRESENTATIVE: Akin, Gump, Strauss, Hauer & Feld, L.L.P.
NUMBER OF CLAIMS: 44
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1631
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating hepatitis virus infection is disclosed. The method comprising administering to a human subject in need of such treatment an effective hepatitis virus-combatting amount of an alkyl lipid or alkyl lipid derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 112989-01-2P 112989-02-3P
(preparation of phospholipids for combating hepatitis B virus)
RN 112989-01-2 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-02-3 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



L5 ANSWER 21 OF 22 USPATFULL on STN
ACCESSION NUMBER: 1999:121339 USPATFULL
TITLE: Lipid analogs for treating viral infections
INVENTOR(S): Kucera, Louis S., Pfafftown, NC, United States

	Morris-Natschke, Susan L., Apex, NC, United States Ishaq, Khalid S., Chapel Hill, NC, United States
PATENT ASSIGNEE(S):	Wake Forest University, Winston-Salem, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5962437		19991005	
	WO 9606620		19960307	
APPLICATION INFO.:	US 1997-793470		19970502	(8)
	WO 1995-US10111		19950807	
			19970502	PCT 371 date
			19970502	PCT 102(e) date

RELATED APPLN. INFO.:	Continuation of Ser. No. US 1994-314901, filed on 29 Sep 1994, now abandoned which is a continuation-in-part of Ser. No. US 1994-297416, filed on 29 Aug 1994, now abandoned
DOCUMENT TYPE:	Utility
FILE SEGMENT:	Granted
PRIMARY EXAMINER:	Raymond, Richard L.
ASSISTANT EXAMINER:	Coleman, Brenda
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.
NUMBER OF CLAIMS:	33
EXEMPLARY CLAIM:	1
LINE COUNT:	1159

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method of treating viral infections, and in particular HIV-1, hepatitis B virus and herpes viruses, is disclosed. The method comprising administering to a subject in need of such treatment an infection-combating amount of a phospholipid or phospholipid derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 178172-98-0 178172-99-1 178173-00-7
178173-01-8
(phospholipids for treating viral infections and tumors)

RN 178172-98-0 USPATFULL

CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(decyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178172-99-1 USPATFULL

CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 4-hydroxy-N,N,N-trimethyl-7-[3-(octyloxy)propoxy]-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-00-7 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheneicosan-1-aminium, 7-[3-(dodecyloxy)propoxy]-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (9CI) (CA INDEX NAME)



RN 178173-01-8 USPATFULL
CN Ethanaminium, 2-[[[2-[2-(dodecyloxy)propoxy]-3-[(1-oxododecyl)amino]propoxy]hydroxyphosphinyl]oxy]-N,N,N-trimethyl-, inner salt (CA INDEX NAME)



L5 ANSWER 22 OF 22 USPATFULL on STN
ACCESSION NUMBER: 1998:72609 USPATFULL
TITLE: Method of treating hepatitis virus infections
INVENTOR(S): Kucera, Louis S., Pfafftown, NC, United States
Morris-Natschke, Susan L., Apex, NC, United States
PATENT ASSIGNEE(S): Wake Forest University, Winston-Salem, NC, United States (U.S. corporation)
University of North Carolina, Chapel Hill, NC, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5770584		19980623
APPLICATION INFO.:	US 1995-465947		19950606 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-74943, filed on 10 Jun 1993, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wilson, James O.		
LEGAL REPRESENTATIVE:	Schwegman, Lundberg, Woessner & Kluth, P.A.		

NUMBER OF CLAIMS: 14
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 1 Drawing Figure(s); 1 Drawing Page(s)
LINE COUNT: 1527
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of treating hepatitis virus infection is disclosed. The method comprising administering to a human subject in need of such treatment an effective hepatitis virus-combatting amount of an alkyl lipid or alkyl lipid derivative.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 112989-01-2P 112989-02-3P 209532-02-5P
209532-03-6P
(alkyl lipids for treating hepatitis virus infections)
RN 112989-01-2 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 112989-02-3 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide (CA INDEX NAME)



RN 209532-02-5 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphaheptacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (+)- (9CI) (CA INDEX NAME)

Rotation (+).



RN 209532-03-6 USPATFULL
CN 3,5-Dioxa-9-aza-4-phosphapentacosan-1-aminium, 7-ethoxy-4-hydroxy-N,N,N-trimethyl-10-oxo-, inner salt, 4-oxide, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




```
=> d his

     (FILE 'HOME' ENTERED AT 11:26:09 ON 14 OCT 2008)

     FILE 'REGISTRY' ENTERED AT 11:26:41 ON 14 OCT 2008
L1             STRUCTURE UPLOADED
L2               7 S L1
L3              70 S L2 FULL

     FILE 'MEDLINE, CAPLUS, WPIDS, USPATFULL' ENTERED AT 11:28:13 ON 14 OCT
     2008
L4              49 S L3
L5              22 S L4 AND VIRUS
L6               0 S L5 AND ("CORONA" OR "TOGA")
L7               2 S L5 AND (CORONAVIRUS OR TOGAVIRUS)

=>

---Logging off of STN---


=>
Executing the logoff script...


=> LOG Y

COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                   ENTRY    SESSION
FULL ESTIMATED COST                                153.80     347.29

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)      SINCE FILE      TOTAL
                                                   ENTRY    SESSION
CA SUBSCRIBER PRICE                                -8.80      -8.80

STN INTERNATIONAL LOGOFF AT 11:30:41 ON 14 OCT 2008
```